FDA on course for repeat oncology approvals performance
This article was originally published in Scrip
Executive Summary
Despite the relentless talk of speeding up product approvals, the US FDA is at least pretty consistent, if not marginally ahead, to repeat the same volume of oncology approvals this year as it did last.